{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:52:23Z","timestamp":1771383143102,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.annder.2020.01.018","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T16:35:06Z","timestamp":1585067706000},"page":"377-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prise en charge de la chromoblastomycose\u00a0: un d\u00e9fi dans les pays \u00e0 ressources limit\u00e9es comme Madagascar"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-3539","authenticated-orcid":false,"given":"F.-A.","family":"Sendrasoa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-F.","family":"Rakotoarisaona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.-M.","family":"Ranaivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.-H.","family":"Razanakoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Raharolahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Andrianarison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ratovonjanahary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Rasamoelina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rapelanoro Rabenja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.-S.","family":"Ramarozatovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2020.01.018_bib0110","series-title":"Medical mycology. The pathogenic fungi and the pathogenic Actinomycetes","first-page":"249","article-title":"Chromoblastomycosis and related dermal infections caused by dematiaceous fungi","author":"Rippon","year":"1982"},{"key":"10.1016\/j.annder.2020.01.018_bib0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3114\/sim.2008.61.14","article-title":"Environmental isolation of black yeast-like fungi involved in human infection","volume":"61","author":"Vicente","year":"2008","journal-title":"Stud Mycol"},{"key":"10.1016\/j.annder.2020.01.018_bib0120","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/0190-9622(91)70292-A","article-title":"Evidence for percutaneous inoculation as the mode of transmission for chromoblastomycosis","volume":"25","author":"Rubin","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.01.018_bib0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4269\/ajtmh.1996.55.45","article-title":"Forty years of chrmoblastomycosis in Madagascar: a review","volume":"55","author":"Esterre","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.annder.2020.01.018_bib0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/CMR.00032-16","article-title":"Chromoblastomycosi","volume":"30","author":"Queiroz-Telles","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.annder.2020.01.018_bib0135","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1590\/S0036-46652015000700009","article-title":"Chromoblastomycosis: a neglected tropical disease","volume":"57","author":"Queiroz-Telles","year":"2015","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.annder.2020.01.018_bib0140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annder.2012.10.605","article-title":"Chromomycose cutan\u00e9e diffuse \u00e0 Phialophora","volume":"140","author":"Radouane","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2020.01.018_bib0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1439-0507.2000.00548.x","article-title":"A case of chromoblastomycosis effectively treated with terbinafine. Characteristics of chromoblastomycosis in the Kitasato region, Japan","volume":"43","author":"Tanuma","year":"2000","journal-title":"Mycoses"},{"key":"10.1016\/j.annder.2020.01.018_bib0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14656566.5.2.247","article-title":"Treating chromoblastomycosis with systemic antifungals","volume":"5","author":"Bonifaz","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.annder.2020.01.018_bib0155","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11046-013-9648-x","article-title":"Challenges in the therapy of chromoblastomycosis","volume":"175","author":"Queiroz-Telles","year":"2013","journal-title":"Mycopathologia"},{"key":"10.1016\/j.annder.2020.01.018_bib0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1590\/abd1806-4841.20187321","article-title":"Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update","volume":"93","author":"Brito","year":"2018","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.annder.2020.01.018_bib0165","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-4362.1992.tb04252.x","article-title":"Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi","volume":"31","author":"Queiroz-Telles","year":"1992","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2020.01.018_bib0170","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1111\/j.1365-2133.1996.tb15658.x","article-title":"Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study","volume":"134","author":"Esterre","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2020.01.018_bib0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09546630410024538","article-title":"Treatment of chromoblastomycosis with terbinafine: experience with four cases","volume":"16","author":"Bonifaz","year":"2005","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.annder.2020.01.018_bib0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/09546630510033203","article-title":"Treatment of chromoblastomycosis with terbinafine: a report of four cases","volume":"16","author":"Xibao","year":"2005","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.annder.2020.01.018_bib0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/AAC.02006-13","article-title":"Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrobial Agent Chemo"},{"key":"10.1016\/j.annder.2020.01.018_bib0190","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/mmy.40.5.529.534","article-title":"Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil","volume":"40","author":"Gupta","year":"2002","journal-title":"Med Mycol"},{"key":"10.1016\/j.annder.2020.01.018_bib0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/myc.12111","article-title":"In vitro susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B","volume":"57","author":"Daboit","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.annder.2020.01.018_bib0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1590\/abd1806-4841.20165142","article-title":"Response of chromoblastomycosis to voriconazole","volume":"91","author":"Lima","year":"2016","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.annder.2020.01.018_bib0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/09546630903585074","article-title":"Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: three cases with relevant improvement under voriconazole therapy","volume":"22","author":"Criado","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.annder.2020.01.018_bib0210","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1590\/S0036-46652005000600006","article-title":"Posaconazole treatment of refractory eumycetoma and chromoblastomycosis","volume":"47","author":"Negroni","year":"2005","journal-title":"Rev Inst Med Trop Sao Paulo"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963820301290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963820301290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:08:27Z","timestamp":1758971307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963820301290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0151963820301290"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2020.01.018","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge de la chromoblastomycose\u00a0: un d\u00e9fi dans les pays \u00e0 ressources limit\u00e9es comme Madagascar","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2020.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}